A combination of medications and lifestyle adjustments can help you manage chronic hives and ease your symptoms.

If you're being treated for hives, your physician will want to hear what you think about your treatment. Is it working? Are your symptoms improving, staying the same, or getting worse? You may be ...

Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested. Dupilumab has been evaluated in phase 3 clinical trials in ...

In patients with chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines, re-treatment with ligelizumab was effective and mostly well tolerated, with both 72-mg and 120-mg doses yielding ...

Improvements in urticaria control and quality of life among patients with chronic inducible urticaria were observed with 20 ...

Chronic spontaneous urticaria (CSU) is responsible for 80% of all cases of chronic hives, but 90% of people never know what causes it. "A lot of times, patients want to know if something they're doing ...

Overall, the CUPID-C trial corroborates earlier evidence that dupilumab can meaningfully reduce itch and hives in ...

In a phase 2 trial, patients having an urticaria exacerbation who used the spray report better hive and pruritus scores than the placebo group.

Panelists discuss how 30%-50% of patients with chronic spontaneous urticaria remain symptomatic despite treatment, examining the impact of treatment burdens, the limitations of targeting the IgE ...

Please provide your email address to receive an email when new articles are posted on . Urticaria patients taking Dupixent experienced an 8.64-point reduction in itch and 15.86-point reduction in ...